Indivior PLC (NASDAQ:INDV) Shares Acquired by Cubist Systematic Strategies LLC

Cubist Systematic Strategies LLC increased its stake in shares of Indivior PLC (NASDAQ:INDV) by 32.0% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 25,236 shares of the company’s stock after acquiring an additional 6,121 shares during the period. Cubist Systematic Strategies LLC’s holdings in Indivior were worth $407,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of INDV. Bank of New York Mellon Corp acquired a new position in shares of Indivior in the second quarter worth about $188,000. VELA Investment Management LLC acquired a new position in shares of Indivior in the 2nd quarter valued at approximately $235,000. XTX Topco Ltd purchased a new position in shares of Indivior during the 2nd quarter valued at approximately $249,000. Cannon Global Investment Management LLC acquired a new stake in shares of Indivior during the first quarter worth approximately $563,000. Finally, Forsta AP Fonden acquired a new stake in shares of Indivior during the first quarter worth approximately $641,000. Hedge funds and other institutional investors own 60.33% of the company’s stock.

Wall Street Analysts Forecast Growth

INDV has been the subject of several research analyst reports. Craig Hallum lowered their price objective on Indivior from $20.00 to $16.00 and set a “buy” rating for the company in a report on Friday. Piper Sandler restated an “overweight” rating and set a $15.00 price objective (down previously from $22.00) on shares of Indivior in a report on Friday.

Indivior Trading Down 6.5 %

NASDAQ:INDV opened at $7.46 on Monday. The company has a market capitalization of $1.03 billion, a P/E ratio of 746.00 and a beta of 0.68. The stock’s 50 day moving average price is $10.99 and its 200 day moving average price is $14.66. The company has a debt-to-equity ratio of 23.50, a quick ratio of 0.68 and a current ratio of 0.85. Indivior PLC has a 52 week low of $7.39 and a 52 week high of $23.22.

Indivior (NASDAQ:INDV) last announced its earnings results on Thursday, July 25th. The company reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.40 by $0.04. Indivior had a negative return on equity of 654.82% and a negative net margin of 12.29%. The firm had revenue of $299.00 million during the quarter, compared to analysts’ expectations of $285.90 million. On average, research analysts forecast that Indivior PLC will post 1.7 EPS for the current fiscal year.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.